Radiopharm Theranostics Limited American Depositary SharesRADX
About: Radiopharm Theranostics Ltd is an Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialization of health technologies.
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.01% less ownership
Funds ownership: 0.02% [Q4 2024] → 0.01% (-0.01%) [Q1 2025]
15% less capital invested
Capital invested by funds: $1.94M [Q4 2024] → $1.65M (-$290K) [Q1 2025]
25% less funds holding
Funds holding: 4 [Q4 2024] → 3 (-1) [Q1 2025]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Maxim Group Michael Okunewitch | 138%upside $12 | Buy Initiated | 1 May 2025 |
Financial journalist opinion
We haven’t received any recent news articles for RADX.